VEGFA and COVID-19: Although improvement of pulmonary functions by anti‐VEGF therapy has been emphasized in this trial, functional improvements of other affected tissues such as liver, kidney, heart, and immune response likely provide additional mechanisms for clinical benefits as these tissues and organs also participate in COVID‐19‐triggered pathological responses.[34]